Positive results from pivotal trials of casgevy™ (exagamglogene autotemcel) highlighted in oral presentations at the american society of hematology (ash) annual meeting and exposition

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced two oral presentations at the american society of hematology (ash) annual meeting and exposition from the global pivotal trials of casgevy™ (exagamglogene autotemcel [exa-cel]). data from 96 patients (44 sickle cell disease [scd], 52 transfusion-dependent beta thalassemia [tdt]) treated with casgevy in pivotal studies, with the longest follow-up of more than four years, continue to reinforce the consiste.
VRTX Ratings Summary
VRTX Quant Ranking